News & Research

Find all the latest research, news and updates on Alzheimer’s disease blood-based biomarkers. Stay up to date with the latest educational materials from the BBM Workgroup.

Featured Stories

Featured

FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease

The Global CEO Initiative on Alzheimer’s Disease Launches Groundbreaking Alzheimer’s Blood Test Performance Database for Clinicians

CEOi Launches Three Part Podcast Series, “A Breakthrough in Alzheimer’s Diagnostics: Integrating Blood Tests into Clinical Practice” in partnership with Pri-Med

BBM Workgroup Activities & Educational Content:

News and Research

Mar 27, 2025

The Global CEO Initiative on Alzheimer’s Disease Launches Groundbreaking Alzheimer’s Blood Test Performance Database for Clinicians

Mar 27, 2025

Jan 14, 2025

CEOi Launches Three Part Podcast Series, “A Breakthrough in Alzheimer’s Diagnostics: Integrating Blood Tests into Clinical Practice” in partnership with Pri-Med

Jan 14, 2025

Oct 25, 2024

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

Oct 25, 2024

Aug 6, 2024

Plain Language Summary of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease”

Aug 6, 2024

Jul 30, 2024

Advancing Patient Care: Clinician Awareness, Attitudes, and Interest in Blood Tests forAlzheimer’s Disease

Jul 30, 2024

Jun 12, 2024

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Jun 12, 2024

May 10, 2024

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

May 10, 2024

Mar 20, 2024

The Global CEO Initiative on Alzheimer’s Disease Announces Expansion of its Blood-Based Biomarker Workgroup in 2024

Mar 20, 2024

Mar 19, 2024

CEOi Blood-Based Biomarker Symposium at AAGP 2024

Mar 19, 2024

Filter by Category: Research articles | News | Press Releases | Workgroup Activities | Education

Emily Scholler 5/20/25 Emily Scholler 5/20/25

FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease

Emily Scholler 1/14/25 Emily Scholler 1/14/25

FDA Grants Breakthrough Device Designation to pTau 217 Blood Test for Alzheimer Disease

Emily Scholler 1/14/25 Emily Scholler 1/14/25

Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use

Emily Scholler 12/30/24 Emily Scholler 12/30/24

Clinical use of biomarkers in the era of Alzheimer's disease treatments

Emily Scholler 11/27/24 Emily Scholler 11/27/24

NeuroVoices: Rebecca M. Edelmayer, PhD, on Advancing Blood Biomarkers in Alzheimer Disease for Earlier Diagnosis and Treatment Intervention

Emily Scholler 10/27/24 Emily Scholler 10/27/24

Blood-based biomarkers for Alzheimer’s present complex challenges to health care system

Emily Scholler 10/25/24 Emily Scholler 10/25/24

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

Emily Scholler 10/23/24 Emily Scholler 10/23/24

WHO Preferred product characteristics of blood-based biomarker diagnostics for Alzheimer disease

Emily Scholler 8/22/24 Emily Scholler 8/22/24

By Setting Standards, Experts Aim to Tame a Wild West of AD Blood Tests

Emily Scholler 8/7/24 Emily Scholler 8/7/24

Blood tests could soon predict your risk of Alzheimer’s

Emily Scholler 8/2/24 Emily Scholler 8/2/24

New blood tests can help diagnose Alzheimer's. Are doctors ready for what's next?

Emily Scholler 6/26/24 Emily Scholler 6/26/24

Why There's New Hope in the Fight Against Alzheimer’s Disease

Emily Scholler 5/10/24 Emily Scholler 5/10/24

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

Emily Scholler 5/10/24 Emily Scholler 5/10/24

FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.

Emily Scholler 4/10/24 Emily Scholler 4/10/24

Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment

Knapsack 3/19/24 Knapsack 3/19/24

CEOi Blood-Based Biomarker Symposium at AAGP 2024

CEOi held a blood-based biomarker symposium at the American Association for Geriatric Psychiatry (AAGP) 2024 Annual Meeting, “Unleashing Diagnostic Innovation: Clinical Implementation of Blood-Based Biomarkers for Alzheimer’s Disease.”

Knapsack 3/7/24 Knapsack 3/7/24

Panel Discussion at AD/PD 2024

CEOi held a panel discussion on the sidelines of AD/PD 2024. The session was moderated by George Vradenburg, Convener of CEOi, and featured Ana Pereira, Mount Sinai; Robert Perneczky, University of Munich; and Richard Batrla, Eisai.

Emily Scholler 2/29/24 Emily Scholler 2/29/24

From St. Louis to Beijing: AD Biomarkers Change Similarly Before Symptoms

Emily Scholler 1/14/24 Emily Scholler 1/14/24

The Hope for Early Detection of Alzheimer’s Disease

Dr. Ali Rezai told 60 Minutes that new developments in blood testing could help doctors identify patients who are at risk for Alzheimer's disease.

Emily Scholler 1/11/24 Emily Scholler 1/11/24

Blood tests can help diagnose Alzheimer's — if they're accurate enough. Not all are

Newer blood tests can help doctors diagnose Alzheimer's disease without a brain scan or spinal tap. But some tests are more accurate than others.

News & Research

Featured Stories

BBM Workgroup Activities & Educational Content:

FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease

FDA Grants Breakthrough Device Designation to pTau 217 Blood Test for Alzheimer Disease

Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use

Clinical use of biomarkers in the era of Alzheimer's disease treatments

NeuroVoices: Rebecca M. Edelmayer, PhD, on Advancing Blood Biomarkers in Alzheimer Disease for Earlier Diagnosis and Treatment Intervention

Blood-based biomarkers for Alzheimer’s present complex challenges to health care system

CEOi submits letter to CMS in response to their proposed reimbursement for brain health biomarkers

WHO Preferred product characteristics of blood-based biomarker diagnostics for Alzheimer disease

By Setting Standards, Experts Aim to Tame a Wild West of AD Blood Tests

Blood tests could soon predict your risk of Alzheimer’s

New blood tests can help diagnose Alzheimer's. Are doctors ready for what's next?

Why There's New Hope in the Fight Against Alzheimer’s Disease

The Global CEO Initiative on Alzheimer’s Disease Comment on the World Health Organization’s Preferred Product Characteristics for Blood Tests for Alzheimer’s Disease

FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.

Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment

CEOi Blood-Based Biomarker Symposium at AAGP 2024

Panel Discussion at AD/PD 2024

From St. Louis to Beijing: AD Biomarkers Change Similarly Before Symptoms

The Hope for Early Detection of Alzheimer’s Disease

Blood tests can help diagnose Alzheimer's — if they're accurate enough. Not all are

Navigation

Follow Us